Download MendeleyHigh-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein.
Klumpp, K., Lam, A.M., Lukacs, C., Vogel, R., Ren, S., Espiritu, C., Baydo, R., Atkins, K., Abendroth, J., Liao, G., Efimov, A., Hartman, G., Flores, O.A.(2015) Proc Natl Acad Sci U S A 112: 15196-15201
- PubMed: 26598693
- DOI: https://doi.org/10.1073/pnas.1513803112
- Primary Citation of Related Structures:
5E0I - PubMed Abstract:
The hepatitis B virus (HBV) core protein is essential for HBV replication and an important target for antiviral drug discovery. We report the first, to our knowledge, high-resolution crystal structure of an antiviral compound bound to the HBV core protein. The compound NVR-010-001-E2 can induce assembly of the HBV core wild-type and Y132A mutant proteins and thermostabilize the proteins with a Tm increase of more than 10 °C. NVR-010-001-E2 binds at the dimer-dimer interface of the core proteins, forms a new interaction surface promoting protein-protein interaction, induces protein assembly, and increases stability. The impact of naturally occurring core protein mutations on antiviral activity correlates with NVR-010-001-E2 binding interactions determined by crystallography. The crystal structure provides understanding of a drug efficacy mechanism related to the induction and stabilization of protein-protein interactions and enables structure-guided design to improve antiviral potency and drug-like properties.
Organizational Affiliation:
Novira Therapeutics, Doylestown, PA 18902; kklumpp@noviratherapeutics.com.
